BMO Capital Markets restated their outperform rating on shares of Horizon Pharma Inc. (NASDAQ:HZNP) in a research report report published on Monday morning. BMO Capital Markets currently has a $29.00 target price on the biopharmaceutical company’s stock.
A number of other research analysts have also recently commented on the company. Citigroup Inc. raised Horizon Pharma from a neutral rating to a buy rating in a report on Monday. Mizuho boosted their price target on Horizon Pharma from $29.00 to $30.00 and gave the stock a buy rating in a report on Tuesday, November 8th. Goldman Sachs Group Inc. set a $26.00 price target on Horizon Pharma and gave the stock a buy rating in a report on Wednesday, October 12th. Vetr raised Horizon Pharma from a buy rating to a strong-buy rating in a report on Monday, October 3rd. Finally, Morgan Stanley reaffirmed a hold rating and set a $24.00 price objective on shares of Horizon Pharma in a report on Wednesday, September 28th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $29.62.
Horizon Pharma (NASDAQ:HZNP) opened at 21.18 on Monday. Horizon Pharma has a one year low of $13.05 and a one year high of $23.44. The company’s market cap is $3.42 billion. The stock has a 50 day moving average of $18.75 and a 200 day moving average of $18.60.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported $0.70 EPS for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.07. Horizon Pharma had a positive return on equity of 22.73% and a negative net margin of 1.34%. The company had revenue of $273.70 million for the quarter, compared to analysts’ expectations of $270.04 million. During the same period in the previous year, the firm earned $0.70 EPS. The firm’s revenue was up 20.8% compared to the same quarter last year. On average, analysts anticipate that Horizon Pharma will post $2.02 earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in Horizon Pharma during the third quarter worth $112,000. Societe Generale acquired a new stake in Horizon Pharma during the second quarter worth $117,000. SG Americas Securities LLC acquired a new stake in Horizon Pharma during the second quarter worth $117,000. Nuveen Asset Management LLC acquired a new stake in Horizon Pharma during the second quarter worth $176,000. Finally, Profund Advisors LLC acquired a new stake in Horizon Pharma during the second quarter worth $194,000. Institutional investors and hedge funds own 86.91% of the company’s stock.
About Horizon Pharma